Your browser doesn't support javascript.
loading
Effect of Tocilizumab on ventilator free days composite outcome in SARS-CoV-2 patients. A retrospective competing risk analysis.
Ahmed F. Mady; Basheer Abdulrahman; Omar E. Ramadan; Shahzad A. Mumtaz; Mohammed A. Al-Odat; Ahmed Kuhail; Rehab Altoraifi; Rayan Alshae; Abdulrahman M. Alharthy; Dimitrios Karakitsos; Waleed Th. Aletreby.
Afiliação
  • Ahmed F. Mady; King Saud Medical City
  • Basheer Abdulrahman; King Saud Medical City
  • Omar E. Ramadan; King Saud Medical City
  • Shahzad A. Mumtaz; King Saud Medical City
  • Mohammed A. Al-Odat; King Saud Medical City
  • Ahmed Kuhail; King Saud Medical City
  • Rehab Altoraifi; King Saud Medical City
  • Rayan Alshae; King Saud Medical City
  • Abdulrahman M. Alharthy; King Saud Medical City
  • Dimitrios Karakitsos; King Saud Medical City
  • Waleed Th. Aletreby; King Saud Medical City
Preprint em Inglês | medRxiv | ID: ppmedrxiv-21254794
ABSTRACT
BackgroundSARS-CoV-2 infection demonstrates a wide range of severity, the more severe cases demonstrate a cytokine storm with elevated serum interleukin-6, hence IL-6 receptor antibody Tocilizumab was tried for the management of severe cases. ObjectivesThe effect of Tocilizumab treatment on the composite outcome of ventilator free days, among critically ill SARS-CoV-2 patients. MethodRetrospective observational propensity score matching study, comparing mechanically ventilated patients upon ICU admission who received Tocilizumab to a control group. Utilizing competing risk analysis method, and reporting sub-distributional hazard ratio of a composite outcome of ventilator free days at day 28. Results29 patients in the intervention group were compared to 29 patients in the control group. Matched groups were similar at base line. The primary outcome of ventilator free days was higher in the intervention group (SHR 2.7, 95% CI 1.2 - 6.3; p = 0.02), crude ICU mortality rate was not different between Tocilizumab and control groups (37.9% versus 62% respectively, p = 0.1), actual ventilator free days were significantly longer in Tocilizumab group (mean difference 4.7 days, 95% CI 1.1 - 8.3; p = 0.02). Sensitivity analysis by Cox regression showed a significantly lower hazard ratio of death in Tocilizumab group (HR 0.49, 95% CI 0.25 - 0.97; p = 0.04). While there was no difference in grown positive cultures among groups (55.2% in Tocilizumab group versus 34.5% in the control, 95% CI of difference -7.11% to 54.4%; p = 0.1). ConclusionTocilizumab may improve the composite outcome of ventilator free days at day 28 among mechanically ventilated SARS-CoV-2 patients, it is associated with significantly longer actual ventilator free days, and insignificantly lower mortality and superinfection.
Licença
cc_by
Texto completo: Disponível Coleções: Preprints Base de dados: medRxiv Tipo de estudo: Experimental_studies / Estudo observacional / Estudo prognóstico / Rct Idioma: Inglês Ano de publicação: 2021 Tipo de documento: Preprint
Texto completo: Disponível Coleções: Preprints Base de dados: medRxiv Tipo de estudo: Experimental_studies / Estudo observacional / Estudo prognóstico / Rct Idioma: Inglês Ano de publicação: 2021 Tipo de documento: Preprint
...